Lysine-Based Small Molecule Sensitizes Rifampicin and Tetracycline against Multidrug-Resistant and .

The priority pathogen list published by the World Health Organization (WHO) has categorized carbapenem-resistant and as the top two critical pathogens, and hence, the development of novel antibacterial strategies to tackle such bacteria is highly necessary. Toward this aim, herein we report the efficacy of the combination of a lysine-based membrane-active small molecule, D-LANA-14 (d-lysine conjugated aliphatic norspermidine analogue bearing tetradecanoyl chain) and the obsolete/inactive antibiotics (such as tetracycline and rifampicin) to combat these superbugs. The combination of D-LANA-14 and the antibiotics tetracycline or rifampicin showed not only synergistic activity against growing planktonic cells of meropenem-resistant and clinical isolates but was also able to disrupt their established biofilms. More importantly, this synergistic effect was retained under the scenario, wherein the combination showed excellent efficacy in mice model of burn-wound infection with a drastic reduction of bacterial burden. A combined treatment of D-LANA-14 (40 mg/kg) and rifampicin (40 mg/kg) showed 4.9 log and 4.0 log reduction in and viability, respectively. On the contrary, individual treatment of D-LANA-14 decreased bacterial burden by 2.3 log () and 1.3 log () and rifampicin reduced about 3.0 log () and 1.6 log (). Owing to the membrane-active nature imparted by D-LANA-14, bacteria could not develop resistance against the combined treatment, whereas a high-level of resistance development was observed against the last resort Gram-negative antibiotic, colistin. Taken together, the results therefore indicate a great potential of this novel combination to be developed as therapeutic regimen to combat infections caused by critical Gram-negative pathogens.